Featured Research

from universities, journals, and other organizations

New test shows promise for detecting warning signs of joint replacement failure

Date:
April 30, 2011
Source:
American Chemical Society
Summary:
A new test shows promise for detecting the early stages of a major cause of failure in joint replacement implants, so that patients can be treated and perhaps avoid additional surgery. More than 1.5 million total joint replacement operations are performed worldwide each year. While the success rate is 90 per cent, almost 10 per cent of implants fail and require additional surgery.

A new test shows promise for detecting the early stages of a major cause of failure in joint replacement implants, so that patients can be treated and perhaps avoid additional surgery. More than 1.5 million total joint replacement operations are performed worldwide each year. While the success rate is 90 per cent, almost 10 per cent of implants fail and require additional surgery, report appears in the ACS journal Molecular Pharmaceutics.

Dong Wang and colleagues at University of Nebraska Medical Center and the Hospital for Special Surgery of New York explain that wear and tear in a joint replacement can create tiny bits of debris that cause local inflammation and lead to bone loss. When this happens, the implant can become loose and set the stage for failure. Treatment usually comes too late, they note, since it's difficult to detect the problem in its early stages. "When pain or clear radiographic evidence is reported, unfortunately, considerable bone loss has already occurred, which cannot be easily restored," the scientists note.

To provide an early diagnostic tool for implant failure, the researchers developed a polymer-based system for imaging the inflammation that is associated with the wear debris. Their tests of the imaging agent in mouse bone suggest that it can help them detect the early stages of bone loss that might cause a joint implant to become loose. They also found that they could tether a powerful anti-inflammatory drug to the polymeric system, offering a way to treat inflammation and bone loss in these early stages of wear. "Subsequent therapeutic interventions at this stage," they write, "would permit prolongation of the lifetime of the implant with improved patient outcomes."

The authors acknowledge funding from the National Institute of Arthritis, Musculoskeletal and Skin Diseases and the American College of Rheumatology Research and Education Foundation.


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ke Ren, Ed Purdue, Lyndsey Burton, Ling-Dong Quan, Edward V Fehringer, Geoffrey M. Thiele, Steven Goldring, Dong Wang. Early detection and treatment of wear particle-induced inflammation and bone loss in a mouse calvarial osteolysis model using HPMA copolymer conjugates. Molecular Pharmaceutics, 2011; 110325153504017 DOI: 10.1021/mp2000555

Cite This Page:

American Chemical Society. "New test shows promise for detecting warning signs of joint replacement failure." ScienceDaily. ScienceDaily, 30 April 2011. <www.sciencedaily.com/releases/2011/04/110427101403.htm>.
American Chemical Society. (2011, April 30). New test shows promise for detecting warning signs of joint replacement failure. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/04/110427101403.htm
American Chemical Society. "New test shows promise for detecting warning signs of joint replacement failure." ScienceDaily. www.sciencedaily.com/releases/2011/04/110427101403.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins